CCCP [555-60-2]

Minimum order 2

Referentie HY-100941-1mL

Formaat : 10mM/1mL

Merk : MedChemExpress


Description

CCCP is an oxidative phosphorylation (OXPHOS) uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation[1].

IC50 & Target

STING[1]
IFN-β[1]

Cellular Effect
Cell Line Type Value Description References
HepG2 IC50
22 μM
Compound: CCCP
Hepatotoxicity in human HepG2 cells assessed as decrease in cell viability after 24 hrs by PrestoBlue assay
Hepatotoxicity in human HepG2 cells assessed as decrease in cell viability after 24 hrs by PrestoBlue assay
[PMID: 27598234]
HepG2 IC50
36 μM
Compound: CCCP
Hepatotoxicity in human HepG2 cells assessed as loss of mitochondrial membrane potential after 24 hrs by JC-1 staining based fluorescence assay
Hepatotoxicity in human HepG2 cells assessed as loss of mitochondrial membrane potential after 24 hrs by JC-1 staining based fluorescence assay
[PMID: 27598234]
HepG2 IC50
6 μM
Compound: CCCP
Hepatotoxicity in human HepG2 cells assessed as decrease in cell viability after 48 hrs by PrestoBlue assay
Hepatotoxicity in human HepG2 cells assessed as decrease in cell viability after 48 hrs by PrestoBlue assay
[PMID: 27598234]
HepG2 IC50
7.2 μM
Compound: CCCP
Hepatotoxicity in human HepG2 cells assessed as intracellular ATP level after 48 hrs by luminescence based ATP detection assay
Hepatotoxicity in human HepG2 cells assessed as intracellular ATP level after 48 hrs by luminescence based ATP detection assay
[PMID: 27598234]
HepG2 IC50
9.8 μM
Compound: CCCP
Hepatotoxicity in human HepG2 cells assessed as intracellular ATP level after 24 hrs by luminescence based ATP detection assay
Hepatotoxicity in human HepG2 cells assessed as intracellular ATP level after 24 hrs by luminescence based ATP detection assay
[PMID: 27598234]
In Vitro

CCCP inhibits IFN-β production induced by various types of the STING pathway activators. CCCP suppresses the phosphorylation of STING, TBK1, and IRF3 via disrupting the association of STING and TBK1. CCCP inhibits activation of STING and its downstream signaling molecules, TBK1 and IRF3, but not STING translocation to the perinuclear region. CCCP impairs the interaction between STING and TBK1 and concomitantly triggers mitochondria fission. Importantly, the knockout of the crucial mitochondria fission regulator Drp1 restored the STING activity, indicating that CCCP down-modulates the STING pathway through DRP1-mediated mitochondria fragmentation. The protonophore CCCP that disrupts membrane potential suppresses the DMXAA-triggered STING signaling pathway. CCCP drastically suppresses the production of IFN-β in DMXAA-treated RAW264.7 cells and MEFs[1].
As low as 1 μM CCCP is enough to induce mitocytosis. In cells treated with 10 μM CCCP, which is the dose used for inducing mitophagy, mitocytosis is barely induced. Mechanistically, mitocytosis requires positioning of damaged mitochondria at the cell periphery, which occurs because damaged mitochondria avoid binding to inward motor proteins[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The same dosage of 3 mg/kg.bw each of CCCP and PPEF is used. In both the cases 1 log reduction is observed in the bacterial load. However, when 3 mg/kg.bw of PPEF is used in combination with 3 mg/kg.bw of CCCP, 6 log10 reduction is observed in the bacterial count. The developed model validates the enhanced antibacterial activity of combination therapy[2].99mTc-MIBI signals in the hearts of SD rats administered CCCP (4 mg/kg intraperitoneally) or vehicle is also measured. 99mTc-MIBI signals decrease in rat hearts administered CCCP, and the ATP content, as measured by 31P magnetic resonance spectroscopy, decreased simultaneously. To investigate whether CCCP decreased the 99mTc-MIBI signals in rats, we analyzed the radioisotope activity of excised heart tissue from rats administered CCCP. At 180 min after 99mTc-MIBI injection, the 99mTc-MIBI signals from the hearts in the CCCP group are significantly lower than those in the vehicle group[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

204.62

Formule

C9H5ClN4

CAS No.
Appearance

Solid

Color

Yellow to brown

SMILES

N#C/C(C#N)=N/NC1=CC=CC(Cl)=C1

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : 50 mg/mL (244.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8871 mL 24.4355 mL 48.8711 mL
5 mM 0.9774 mL 4.8871 mL 9.7742 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (12.22 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Pureté et documentation
Références

Misschien heeft u ook interesse in de volgende producten:



Referentie
Beschrijving
Cond.
Price Bef. VAT
NB-64-35381-1mL
 1mLx10mM(inDMSO) 
NB-64-18580-1mL
 1mLx10mM(inDMSO) 
NB-64-10638-1mL
 1mLx10mM(inDMSO)